Article 20 May 2024 "Half-Truths," Not "Pure Omissions": Supreme Court Limits Section 10(b) Claims Based On Item 303 Nondisclosure To Omissions That Render Affirmative Statements Misleading United States Litigation
Article 28 Apr 2024 Securities Litigation Alert: "Half-Truths," Not "Pure Omissions": Supreme Court Limits Section 10(b) Claims Based On Item 303 Nondisclosure To Omissions That Render Affirmative Statements Misleading United States Commercial
Article 27 Sep 2023 Fact Or Fiction: The US Courts' Struggle To Determine When Opinion Statements Are Actionable Under Federal Securities Laws United States Litigation
Article 02 Jun 2023 Securities Litigation Alert: Ninth Circuit Clarifies Standards Governing The Statute Of Limitations For Private Claims Under Section 10(b) Of The Securities Exchange Act Of 1934 United States Commercial
Article 18 Apr 2023 Second Circuit Confirms That Item 303 Disclosure Violations May Support Section 10(b) Liability In Reviving Claims Based On Failure To Disclose Risks From Harmful-Emission Regulation United States Commercial
Article 17 Mar 2023 DOJ Pilot Program Incentivizes Clawbacks And Instructs Corporations To Preserve Business Communications On Employees' Personal Devices United States Commercial
Article 25 Jan 2023 Securities Litigation Alert: Second Circuit Adopts Restrictive View Of Purchaser-Seller Rule, Limiting Section 10(b) Standing To Transactions In Securities Of Company "About Which" Alleged Misstatements Were Made United States Commercial
Article 03 Jun 2022 SEC Commissioner Signals Need To Fulfill Mandate Of Sarbanes-Oxley Act And Develop "Minimum Standards" For Lawyers Practicing Before The Commission United States Commercial
Article 18 Apr 2022 Securities Litigation Update: Courts Of Appeal Address The Exchange Act's Exclusive-Jurisdiction And Non-Waiver Provisions, The Duty To Disclose, And Scienter United States Commercial
Article 20 Jan 2022 Securities Litigation Update: Federal Courts Allow Section 10(b) Claims Based On Non-Fraudulent "Channel Stuffing" And Hyped COVID-19 Vaccine Candidate United States Commercial